Are peptides safe? It depends on which peptide and where it comes from. FDA-approved peptides such as semaglutide and tirzepatide have well-characterized risks from trials in thousands of people, printed on their labels.[1][2] Compounded versions have shown 2.35 times higher odds of hospitalization in FDA adverse event reports,[4] and “research” peptides bought online have tested as low as 7.7% pure with bacterial toxins in every sample.[8]
“Peptide” describes a chemical structure, a short chain of amino acids. It says nothing about safety. Insulin is a peptide; so is a snake venom toxin. This guide explains the three supply routes, what the adverse event and contamination data show, and how to lower your risk. For background, see our peptide basics hub.
Evidence-graded table
| Peptide or drug | Evidence level | What was shown on safety | FDA status | Our profile |
|---|---|---|---|---|
| Semaglutide (brand) | FDA-approved | GI side effects common; boxed thyroid tumor warning from rodents[1] | Approved | Semaglutide |
| Tirzepatide (brand) | FDA-approved | Similar GI profile and boxed warning[2] | Approved | Tirzepatide |
| Compounded semaglutide or tirzepatide | Adverse event reports | More reported hospitalization, contamination and preparation errors[4] | Not FDA-approved[3] | Compounded tirzepatide |
| MK-677 | Human RCTs | Raised blood sugar and lowered insulin sensitivity[15] | Not approved; FDA safety-risk list[13] | MK-677 |
| Melanotan II | Case reports | Changes in moles; four melanoma case reports[14] | Not approved | Melanotan II |
| BPC-157 | Animal data, tiny human series | Long-term human safety unknown[17] | Not approved | BPC-157 |
| TB-500 | Animal or lab only | Products often don’t match label[11] | Not approved | TB-500 |
The three supply routes
1. FDA-approved drugs. Made under current good manufacturing practice, tested in clinical trials, and sold with a label listing known risks. Examples include GLP-1 drugs, insulin, tesamorelin and bremelanotide. Our FDA-approved peptides list covers them all.
2. Compounded drugs. Mixed by a state-licensed pharmacy (503A) or an FDA-registered outsourcing facility (503B) for a prescription. FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.[3] See compounded vs research-grade peptides.
3. “Research use only” products. Sold online with labels such as “not for human consumption.” They are not drugs under any approval pathway, and there is no assurance of what’s inside. Read more in our guide to research use only peptides.
What adverse event data show
Compounded GLP-1 drugs. A study of FDA’s adverse event database from 2018 to 2024 found 707 reports involving compounded GLP-1 products among 81,078 GLP-1 reports. Compared with brand products, compounded ones had higher reporting odds for abdominal pain, preparation errors, contamination and hospitalization (odds ratio 2.35).[4] Reporting databases can show signals but cannot prove cause.
Dosing errors. Compounded semaglutide often comes in multi-dose vials with separate syringes, not prefilled pens. A poison center case series described patients who injected 10 times their intended dose after confusion between milliliters, units and milligrams.[5] At another US poison center, 69% of 237 GLP-1 calls over nine years involved unintentional dosing errors.[6] FDA issued its own alert about these errors in 2024.[7]
Unapproved peptides. For most, there is no systematic safety data at all. FDA’s list of compounding substances with significant safety risks cites concerns such as immune reactions, peptide impurities and very limited human data.[13] A 2026 review warned of contamination, inaccurate dosing and theoretical risks such as abnormal blood vessel growth from unregulated injectables.[16]
What contamination studies found
Independent labs that buy and test these products keep finding problems:
- Semaglutide sold online without a prescription: purity of only 7.7% to 14.4%, content 29% to 39% above the label, and bacterial endotoxin in every vial.[8]
- Falsified peptide drugs in Belgium: purity as low as 5%, plus arsenic and lead in some samples at up to 10 times the safety limit for injectable drugs.[9]
- Black-market growth products: a modified growth hormone and altered versions of GHRP-2, GHRP-6 and ipamorelin that had never been tested in people.[10]
- TB-500 products: contents not consistently matching their descriptions.[11]
- Custom-made peptides: an undeclared filler making up 20% to 43% of two samples, missed by standard purity tests.[12]
A seller’s certificate of analysis can’t fix these problems if the seller is the one writing it. Our guides to counterfeit peptides and reading a peptide COA go deeper.
Side effects to know about
Even approved peptides have real side effects. GLP-1 drugs commonly cause nausea, vomiting, diarrhea and constipation, and carry warnings for pancreatitis, gallbladder disease and low blood sugar when combined with insulin.[1][2] Injection site reactions are possible with any injected peptide. See our overviews of peptide side effects and injection site reactions.
Common safety myths
“Peptides are natural, so they’re safe.” Many unapproved peptides are lab-made fragments or modified versions of body proteins, and some, such as the altered GHRPs found on the black market, have never been given to people in a study.[10] Being similar to a natural molecule doesn’t predict how a concentrated injected dose behaves.
“It’s been used for years without problems.” Without systematic tracking, problems go unseen. Adverse event reporting for unapproved products is sparse, and FDA has cited “very limited” human safety data as a reason for concern about many peptides.[13]
“My vial came with a lab report.” Testing can miss impurities. In one study, a filler made up as much as 43% of a custom peptide yet was invisible to the standard liquid chromatography test.[12]
“Approved means there are no risks.” It doesn’t. Approved GLP-1 drugs carry a boxed warning about thyroid C-cell tumors seen in rodents and are not for people with certain thyroid cancers.[1][2] Approval means the risks are known, measured and weighed against proven benefits.
Who should be extra cautious
- Pregnant or breastfeeding people: most peptides have no pregnancy safety data, and approved GLP-1 labels advise stopping before a planned pregnancy.[1]
- Children and teens: only a handful of peptides are approved for young people, each for a specific diagnosis.
- People with a history of cancer: peptides that raise growth hormone or IGF-1, or promote blood vessel growth, raise theoretical concerns that have not been studied.[16]
- People with diabetes: MK-677 raised fasting blood sugar in older adults,[15] and GLP-1 drugs can cause low blood sugar with insulin.[1]
- Competitive athletes: many peptides are banned in sport. BPC-157 has only limited, low-quality human evidence even for its main use.[17]
How to lower your risk
- Use a prescription and a licensed pharmacy. Our guide to checking a compounding pharmacy explains how.
- Know your dose in milligrams, not just “units,” and confirm how to measure it.
- Be wary of animal-only evidence. Results in rats often don’t hold up in people; see animal vs human peptide studies.
- Talk to a clinician first. Our guide on talking to your doctor about peptides can help, and peptide clinic vs DIY covers the trade-offs.
- Report problems to FDA’s MedWatch program.[18]
